Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients

NCT05274048 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT05274048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05274048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 24, 2022
Completion date
June 30, 2028
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastrointestinal cancer, her2 gene mutation